RxDoctor Payments Data

Richard Whitley

Pediatric Infectious Diseases · Birmingham, ALNPI 1649287871

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,126,259 of the $1,173,821 with a category attached, or 95.9%. Gilead accounts for 91.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $476,085 and has fallen 92.4% since, to $36,353 in 2025.

$1,173,821in general payments, 2019–2025

Across 203 payments — averaging $5782.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1.1M
  • Visby Medical, Inc.$40K
  • Merck$27K
  • GSK$18K
  • Modernatx, Inc.$8K
  • PTC Therapeutics, Inc.$3K
  • plus $965 from 2 others

What the payments were for

  • Consulting fees$1,126,25996%
  • Speaking & faculty fees$3950%
  • Travel & lodging$43,0464%
  • Food & beverage$4,1210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead145$1,076,920
Visby Medical, Inc.8$40,000
Merck24$27,413
GSK18$17,623
Modernatx, Inc.1$8,100
PTC Therapeutics, Inc.2$2,800
Sanofi-aventis U.S. LLC4$570
F. Hoffmann-la Roche AG1$395

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric infectious diseases providers in Alabamato place this figure against a meaningful peer group, so we don't.

Other pediatric infectious diseases in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →